300 CONNELL DRIVE, BERKELEY HEIGHTS, NJ
Announces Preliminary THIRD Quarter 2025 Results and RAISES 2025 NET REVENUE GUIDANCE
Amended material disclosure
Completes Acquisition of Melinta Therapeutics and Announces New Leadership Team
News, Securities Holder Rights or Indentures
Material Contracts, Financial Results, Unregistered Sales of Equity Securities, Reg. FD, Other Events
ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK
Shareholder votes
Announces Customer Implementation
Q2
Q1
FY 2024
Q3
FY 2023
S-3ASR
RW
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Definitive Proxy Statement
PRER14A
PRE 14A
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Notice of Proposed Sale of Securities
Correspondence
Submission Upload